Who owns ACRIVON THERAPEUTICS INC?
- Ticker: ACRV
- CUSIP Number: 004890109
Tip: Access positions for across all investors
Analyze quarterly positions in Acrivon Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Acrivon Therapeutics stock
Who bought or sold ACRIVON THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 4.8M | $34M | 0% | Mar 2024 |
|
| Perceptive Advisors | 3.0M | $22M | 0% | Mar 2024 |
|
| Citadel Advisors | 1.7M | $12M | 2% | Mar 2024 |
|
| Sands Capital Ventures | 1.7M | $12M | 0% | Mar 2024 |
|
| Wellington Management Company | 888k | $4.4M | 0% | Dec 2023 |
|
| BlackRock | 744k | $5.3M | 41% | Mar 2024 |
|
| Marshall Wace | 598k | $4.3M | 0% | Mar 2024 |
|
| Vanguard Group | 507k | $3.6M | 7% | Mar 2024 |
|
| Geode Capital Management | 243k | $1.7M | 28% | Mar 2024 |
|
| Federated Investors | 226k | $1.1M | 0% | Dec 2023 |
|
| DAFNA Capital Management | 131k | $939k | 0% | Mar 2024 |
|
| UBS O'Connor | 127k | $908k | 100% | Mar 2024 |
|
| Northern Trust | 108k | $770k | 48% | Mar 2024 |
|
| Millennium Management | 96k | $683k | 100% | Mar 2024 |
|
| Charles Schwab Investment Management | 77k | $553k | 13% | Mar 2024 |
|
| Bridgeway Capital Management | 58k | $416k | 100% | Mar 2024 |
|
| Exchange Traded Concepts | 56k | $402k | 323% | Mar 2024 |
|
| Baker Bros. Advisors | 53k | $378k | 100% | Mar 2024 |
|
| Bank of New York Mellon | 24k | $175k | -2% | Mar 2024 |
|
| Barclays | 21k | $153k | -13% | Mar 2024 |
|
| Morgan Stanley | 17k | $123k | 249% | Mar 2024 |
|
| Springbok Capital Management | 13k | $93k | 100% | Mar 2024 |
|
| UBS Group | 13k | $91k | 100% | Mar 2024 |
|
| Nuveen Asset Management | 12k | $85k | 0% | Mar 2024 |
|
| Rhumbline Advisers | 11k | $78k | 17% | Mar 2024 |
|
| AAFCPAs Wealth Management | 11k | $76k | 0% | Mar 2024 |
|
| Raymond James & Associates | 10k | $73k | 100% | Mar 2024 |
|
| Bank of America Corporation | 6.0k | $43k | -40% | Mar 2024 |
|
| Advisor Group Holdings | 5.1k | $36k | 100% | Mar 2024 |
|
| Jpmorgan Chase & Co | 5.0k | $35k | -85% | Mar 2024 |
|
| Citigroup | 4.5k | $32k | 122% | Mar 2024 |
|
| American International | 4.3k | $21k | 0% | Dec 2023 |
|
| Wells Fargo & Company | 4.3k | $31k | 60% | Mar 2024 |
|
| New York State Common Retirement Fund | 2.3k | $16k | 0% | Mar 2024 |
|
| California State Teachers Retirement System | 1.2k | $8.8k | -36% | Mar 2024 |
|
| FMR | 1.0k | $7.3k | 257% | Mar 2024 |
|
| Legal & General Group | 839.00 | $5.9k | 0% | Mar 2024 |
|
| Tower Research Capital | 817.00 | $5.8k | -35% | Mar 2024 |
|
| OTR - Nominee Name for The State Teachers Retirement Board of Ohio | 800.00 | $5.0k | 0% | Mar 2024 |
|
| Summit Investment Advisors | 695.00 | $5.0k | 0% | Mar 2024 |
|
| Amalgamated Bank | 378.00 | $3.0k | -69% | Mar 2024 |
|
| Royal Bank of Canada | 278.00 | $0 | -89% | Mar 2024 |
|
| Russell Investments | 223.00 | $1.6k | 100% | Mar 2024 |
|
| Efficient Wealth Management | 88.00 | $999.996800 | 100% | Mar 2024 |
|
| Capital Advisors | 48.00 | $0 | 100% | Mar 2024 |
|
| CWM | 3.00 | $0 | 100% | Mar 2024 |
|
Who sold out of Acrivon Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| NEA Management Company | Dec 2023 | 430k | $1.3M |
| Jacobs Levy Equity Management | Dec 2023 | 46k | $227k |
| D. E. Shaw & Co | Dec 2023 | 32k | $157k |
| Qube Research & Technologies | Sep 2023 | 138.00 | $1.3k |